EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL

doi:10.1158/1538-7445.AM2018-LB-259

	EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL
	Xie, Shao; Wei, Fan; Sun, Yiming; Gao, Yinglei; Ding, Jian; Chen, Yi
刊名	CANCER RESEARCH
	2018-07-01
卷号	78 期号:13 页码:2
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2018-LB-259
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000468818900405
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/289645]
专题	中国科学院上海药物研究所
作者单位	Shanghai Inst Mat Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Xie, Shao,Wei, Fan,Sun, Yiming,et al. EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL[J]. CANCER RESEARCH,2018,78(13):2.
APA	Xie, Shao,Wei, Fan,Sun, Yiming,Gao, Yinglei,Ding, Jian,&Chen, Yi.(2018).EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL.CANCER RESEARCH,78(13),2.
MLA	Xie, Shao,et al."EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL".CANCER RESEARCH 78.13(2018):2.